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Background: Human parvovirus B19 (B19V) is a frequent contaminant of blood and plasma-derived medicinal
products. To ensure the quality and safety of plasma-derived products, European regulations, Plasma Protein
Therapeutics Association (PPTA) standard and FDA guidelines require testing of manufacturing plasma for
parvovirus B19 DNA to limit the load of this virus. In China, however, there have been no related documentation
and technical guiding principles for monitoring B19V, moreover, an adequate level of information on the
prevalence of B19V in Chinese plasma donations is not available.
Findings: By using an in-house quantitative polymerase chain reaction (qPCR) assay adapted for all three
genotypes of B19V, 235 source plasma pools from three regional different Chinese manufacturers of blood products
were screened and quantified. Results showed that 71.91 % (169/235) of plasma pools were contaminated by B19V,
with the concentrations of 5.18 × 102–1.05 × 109 IU/mL. Approximately 31.95 % of the DNA-positive plasma pools
were only moderately contaminated (<104 IU/mL), while 68.05 % contained >104 IU/mL.
Conclusions: The high level of B19V in plasma pools could present a great risk in plasma derivatives. Therefore, the
implementation of B19V NAT (Nucleic Acid Testing) assays capable of detecting all B19V genotypes and discard
donations with high titer B19V DNA for Chinese blood products manufacturers seems to be necessary.
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Human parvovirus B19 (B19V), a widespread human
pathogen that be associated with a broad range of clin-
ical manifestations, including erythema infectiosum (also
called fifth disease), arthritis, transient aplastic crisis
(TAC), chronic anemia, hydrops fetalis, and fetal death,
can be transmitted via the administration of contami-
nated blood and plasma-derived products [1–5].
Due to the difficulty in removing and inactivating
B19V, the most effective measure for mitigating the risk
of B19V transmission through plasma derivatives should
be limiting the virus load in the manufacturing plasma
pools. Since the early 21st century, U.S. Food and Drug* Correspondence: mayuyuan07@hotmail.com; zhangjg@nic.bmi.ac.cn
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Eur.) and the Plasma Protein Therapeutics Association
(PPTA) have developed a list of standards, proposing a
limit of 104 IU/ml for levels of B19V DNA in source
plasma pools destined for manufacturing some or all kinds
of plasma-derived products [6–10]. After the introduction
of NAT (nucleic acid testing), both the prevalence and
level of B19V DNA within plasma pools and their result-
ing products were significantly lowered [11]. B19V is now
formally subdivided into three distinct genotypes (1, 2, 3),
which were defined as having approximately 10 % diver-
gence in overall DNA sequence [12]. Since all genotype
variants can be contaminants of blood and blood-derived
products, so the NAT assay as an in-process test used in
the manufacturing of plasma-derived products must be
able to detect all genotype variants [13, 14].istributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
t to the original author(s) and the source, provide a link to the Creative
re made. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Primers and probe-binding sequence of the in-house B19 DNA assays. The reference sequences of three B19 virus genotypes are aligned.
Primers sequences were underlined with solid lines, and probe sequence was underlined with dashed line. B19 Genotype 1 sequence
M13178 is used as reference sequence. For B19 Genotype 2 and 3, the Lali strain [GenBank: AY044266] and V9 strain [GenBank:
NC-004295] are included in this alignment
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and technical guidelines for monitoring B19V. There
are about 33 manufacturers for blood products in
China, however, B19V NAT screening of plasma has
never been implemented in the manufacturing of
plasma-derived products. Published data on the preva-
lence of B19V DNA in plasma pools are limited to the
study by Zhang et al., whose investigation was restricted
to 142 plasma pools from two of these manufacturers
(one was located in the south of China, whereas the
other’s location was not mentioned), indicating that the
positive rates of B19V DNA in plasma pools were rela-
tively high (54.23 %) [15].
In this study, we aimed to test a total of 235 source
plasma pools, collected between 2008 and 2013, from
other three Chinese blood products manufacturers
(Manufacturer A, B and C, respectively located in cen-
tral, northern and south-western China). The collec-
tions of plasma samples were approved by the National
Health and Family Planning Commission of the People’s
Republic of China, and all of the donators providedFig. 2 Standard curve of the real-time qPCR assay for B19V DNA. a Amplifi
containing standard plasmid of B19V from 1 × 108 to 1 × 101 template cop
PCR standard curve generated from plasmid DNA amplification plots(a). Th
y-axis represents the fluorescence data used for Cq determinations. The ass
with an R2 of 1.000, the slope value of −3.299 and reaction efficiencies of 1informed consent. Each batch of the plasma pools con-
sisted of 2000 to over 8300 donations. Each donation
mixed in the plasma pools was tested for aminotransferase
(ALT), anti-syphilis, anti-HIV 1/2, HBsAg and anti-HCV
before pooling. All the donations were confirmed to be
qualified according to the requirements of Pharmacopeia
of the People’s Republic of China [16]. Viral DNA was
extracted from a volume of 200 μL pooled source plasma
by using the High Pure Viral Nucleic Acid Kit (Roche
Diagnostics, Mannheim, Germany) according to manufac-
turer’s instructions. Nucleic acids were eluted from the
filter column with 50 μL of nuclease-free double-distilled
water and were stored at −20 °C until further use.
Quantification of B19 DNA was performed by using
an in-house developed qPCR assay adapted for all three
genotypes of B19V. Primers B19F (5′-CGGGACCA
GTTCAGGAGAAT-3), B19R (5′-CCCAACTAACAG
TTCACGAAACT-3′) and probe B19P (5′-AATCATTT
GTCGGAAGCCCAGTTTCC-3′) were designed to specif-
ically amplify a 121-bp fragment derived from the NS1 gene
of B19V (nucleotides 2073–2193, GenBank accession no.cation plots showing the testing in duplicate of a 10-fold dilution series
ies per μL, and the IC plasmid at 120 copies per reaction. b Real-time
e x-axis represents B19V standard plasmid in 10-fold dilutions and the
ay was linear in the range of 1 × 108 to 1 × 101 template copies per μl,
01.0 %
Table 1 Distribution of the B19V DNA load in source plasma pools
B19V DNA load (IU/mL) Number of lots (%)
Manufacturer A Manufacturer B Manufacturer C Total
109 ~ 1010 1 (0.71) 0 1 (1.35) 2 (0.85)
108 ~ 109 7 (4.96) 2 (10.00) 1 (1.35) 10 (4.26)
107 ~ 108 4 (2.84) 4 (20.00) 2 (2.70) 10 (4.26)
106 ~ 107 5 (3.55) 2 (10.00) 9 (12.16) 16 (6.81)
105 ~ 106 19 (13.48) 4 (20.00) 8 (10.81) 31 (13.19)
104 ~ 105 36 (25.53) 5 (25.00) 5 (6.76) 46 (19.57)
Positive ~ 104 32 (22.70) 3 (15.00) 19 (25.68) 54 (22.98)
Number of positive lots 104 (73.76) 20 (100.00) 45 (60.81) 169 (71.91)
Number of negative lots 37 (26.24) 0 29 (39.19) 66 (28.09)
Number of lots tested 141 20 74 235
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control) contained the identical sequence of the B19 target
sequence but with an altered probe hybridization site (ICP:
5′-AATTCGATCTTGGACCAGCAGTTCTC-3′), was in-
cluded in each sample to prevent false negative results. This
allows co-amplification of B19V and IC and co-detection
of HEX (5-Hexachlorofluorescein) or FAM (6-carboxyflu-
orescein) labeled probes respectively. Three microliters of
DNA was added to a reaction mixture (in a final volume
of 20 μL) containing 10 μL of Platinum Quantitative PCR
SuperMix-UDG (Invitrogen Life Technologies, Paisley,
United Kingdom), 500nM of each primer, and 250nM of
each probe for amplification of DNA from the B19V and
IC. Amplification and detection were carried out on
the Bio-Rad MiniOpticon Real-Time PCR System (Bio-
Rad Laboratories, Hercules, USA) with the following
thermal cycle conditions: 2 min of incubation at 50 °C,
2 min of pre-denaturation at 95 °C, 40 cycles in two steps
each (95 °C for 9 s, 60 °C for 30 s). Standard curves were
generated with serial log 10 dilutions ranging from 108
to 101 copies per μL of the B19V standard plasmid con-
taining the 121-bp PCR product. One hundred and
twenty copies of the IC plasmid were included in eachFig. 3 Multiple sequence alignment of the B19V prototype isolate [GenBanwell and all samples were analyzed in duplicate. The
assay was shown to be linear over this eight orders of mag-
nitude. The IC DNA could be detected when B19V plas-
mid lower than 103 copies per μL and in the no template
control (NTC) well (Fig. 2). The performance of this
NAT assay was evaluated with the 1st WHO Inter-
national Reference Panel for Parvovirus B19 Genotypes
for NAT based assays (NIBSC code: 09/110). This
assay was able to detect all three B19 virus genotypes
with the sensitivity of 5 copies per reaction, and the
conversion ratio from copies to IU is 5.08:1, indicating
that 5.08 B19V copies/mL measured by our real-time
qPCR assay was equivalent to 1 IU/mL.
As indicated in Table 1, 72 % (169/235) of the sam-
ples contained detectable levels of B19V and the
amount of DNA ranged from 5.18 × 102 to 1.05 ×
109 IU/mL plasma. Forty-nine percent (115/235) of
plasma pools contained B19V DNA at concentrations
exceeding 104 IU/mL. In the case of manufacturer B, the
positive rate of B19V DNA in plasma pools was 100 %,
higher than that from manufacturer A (73.76 %) and
manufacturer C (60.81 %). Positive rates of B19V DNA
in plasma pools from three manufacturers werek: M13178.1] and isolates identified in pools
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chi-square test). Above results showed that both of the
prevalence and levels of B19V DNA in plasma pools
tested in our study were higher than that of previous
reports in China (54.20 %) and investigations in other
countries before NAT was introduced (56.10 % ~ 59.68 %)
[15, 17, 18]. Besides, there were large differences among
the positive rates of industrial plasma pools of five manu-
factures (three in our study and the other two in previous
report) in China, ranging from 30 to 100 %. These diver-
sities may reflect geographic differences in the spread of
the virus in diverse parts of the world, methodological
differences in diagnostic procedures, differences in sam-
ple size, or differences in number of plasma units within
each pool sample.
To confirm the accuracy of the NAT procedure,
PCR products of the positive samples were cloned
into pMD18-T vector (Takara Bio, Dalian, China) and
sequenced using ABI 3730 and accessories. Then the
sequences were aligned with the sequence of B19V proto-
type isolate (GenBank accession no. M13178.1) using
DNAStar software package. Sequencing and alignment
of amplification products of the positive samples
revealed that they exhibited 90.24 %~100 % identity
with the prototype (Fig. 3).
In conclusion, the data present demonstrates a rela-
tively high prevalence of B19V in Chinese plasma
pools. Therefore, to reduce the risk of B19V transmis-
sion, the implementation of B19V NAT assays capable
of detecting all B19V genotypes and discard donations
with high titer B19V DNA for Chinese blood products
manufacturers seems to be necessary.
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